Annual Short Term Debt
$18.60 M
+$1.91 M+11.47%
December 31, 2023
Summary
- As of February 8, 2025, NTLA annual short term debt is $18.60 million, with the most recent change of +$1.91 million (+11.47%) on December 31, 2023.
- During the last 3 years, NTLA annual short term debt has risen by +$12.90 million (+226.53%).
- NTLA annual short term debt is now at all-time high.
Performance
NTLA Short Term Debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Short Term Debt
$19.18 M
+$214.00 K+1.13%
September 30, 2024
Summary
- As of February 8, 2025, NTLA quarterly short term debt is $19.18 million, with the most recent change of +$214.00 thousand (+1.13%) on September 30, 2024.
- Over the past year, NTLA quarterly short term debt has increased by +$2.10 million (+12.32%).
- NTLA quarterly short term debt is now at all-time high.
Performance
NTLA Quarterly Short Term Debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Short Term Debt Formula
Short-Term Debt = Current Portion of Long-Term Debt + Short-Term Loans + Commercial Paper + Other Short-Term Borrowings
NTLA Short Term Debt Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +11.5% | +12.3% |
| 3 y3 years | +226.5% | +120.3% |
| 5 y5 years | +100.0% | +248.4% |
NTLA Short Term Debt Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +104.1% | at high | +110.5% |
| 5 y | 5-year | at high | +226.5% | at high | +236.8% |
| alltime | all time | at high | -100.0% | at high | -100.0% |
Intellia Therapeutics Short Term Debt History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $19.18 M(+1.1%) |
| Jun 2024 | - | $18.96 M(+1.1%) |
| Mar 2024 | - | $18.76 M(+0.9%) |
| Dec 2023 | $18.60 M(+11.5%) | $18.60 M(+8.9%) |
| Sep 2023 | - | $17.07 M(+1.9%) |
| Jun 2023 | - | $16.75 M(+2.6%) |
| Mar 2023 | - | $16.33 M(-2.1%) |
| Dec 2022 | $16.68 M(+83.1%) | $16.68 M(+23.1%) |
| Sep 2022 | - | $13.55 M(+41.6%) |
| Jun 2022 | - | $9.57 M(+2.5%) |
| Mar 2022 | - | $9.34 M(+2.5%) |
| Dec 2021 | $9.11 M | $9.11 M(+4.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2021 | - | $8.71 M(+17.4%) |
| Jun 2021 | - | $7.42 M(-10.2%) |
| Mar 2021 | - | $8.26 M(+44.9%) |
| Dec 2020 | $5.70 M(-0.9%) | $5.70 M(-8.1%) |
| Sep 2020 | - | $6.20 M(+6.2%) |
| Jun 2020 | - | $5.83 M(+2.5%) |
| Mar 2020 | - | $5.69 M(-0.9%) |
| Dec 2019 | $5.75 M(>+9900.0%) | $5.75 M(+4.4%) |
| Sep 2019 | - | $5.50 M(+8.7%) |
| Jun 2019 | - | $5.07 M(+15.6%) |
| Mar 2019 | - | $4.38 M(>+9900.0%) |
| Dec 2018 | $0.00 | $0.00 |
FAQ
- What is Intellia Therapeutics annual short term debt?
- What is the all time high annual short term debt for Intellia Therapeutics?
- What is Intellia Therapeutics annual short term debt year-on-year change?
- What is Intellia Therapeutics quarterly short term debt?
- What is the all time high quarterly short term debt for Intellia Therapeutics?
- What is Intellia Therapeutics quarterly short term debt year-on-year change?
What is Intellia Therapeutics annual short term debt?
The current annual short term debt of NTLA is $18.60 M
What is the all time high annual short term debt for Intellia Therapeutics?
Intellia Therapeutics all-time high annual short term debt is $18.60 M
What is Intellia Therapeutics annual short term debt year-on-year change?
Over the past year, NTLA annual short term debt has changed by +$1.91 M (+11.47%)
What is Intellia Therapeutics quarterly short term debt?
The current quarterly short term debt of NTLA is $19.18 M
What is the all time high quarterly short term debt for Intellia Therapeutics?
Intellia Therapeutics all-time high quarterly short term debt is $19.18 M
What is Intellia Therapeutics quarterly short term debt year-on-year change?
Over the past year, NTLA quarterly short term debt has changed by +$2.10 M (+12.32%)